This article discusses the newest investigational treatment for demodex blepharitis, TP-03 (lotilaner 0.25% ophthalmic solution; Tarsus Pharmaceuticals). Three optometrists dive into the treatment's importance, history and the results of completed clinical trials.
Supported by Tarsus Pharmaceuticals